These findings reconcile the decline in tumor‐infiltrating T cells observed in tumors developing resistance with the CD8+‐dependent therapeutic benefit of ECM inhibition, highlighting the ECM as a critical regulator of immune accessibility in melanoma. Here, CD8A is linked to neoplasm.